Stent with ring architecture and axially displaced connector segments
First Claim
Patent Images
1. An expandable stent, comprising:
- a main body having a first end, a second end, and a longitudinal axis extending from the first end to the second end, the main body comprising a plurality of ring structures, each of said plurality of ring structures comprising an endless undulating pattern; and
a plurality of connector segments joining first and second ring structures of said plurality of ring structures, each o said plurality of connector segments having an undulating portion axially displaced along the longitudinal axis from said undulating portion of a circumferentially adjacent one of said plurality of connector segments.
2 Assignments
0 Petitions
Accused Products
Abstract
An expandable stent is provided. The stent has a ring architecture in which a plurality of connector segments join a plurality of ring structures to form the stent. The ring structures are an endless pattern of unit structures, each of which has two lateral arms and a central portion, and is inverted with respect to the immediately adjacent unit structures of the same ring structure. The connector segments have an undulating portion and are preferably axially displaced relative to other, circumferentially adjacent connector segments when the stent is in an unexpanded configuration. A delivery system that includes a stent accordingly to the present invention is also provided.
-
Citations
30 Claims
-
1. An expandable stent, comprising:
-
a main body having a first end, a second end, and a longitudinal axis extending from the first end to the second end, the main body comprising a plurality of ring structures, each of said plurality of ring structures comprising an endless undulating pattern; and
a plurality of connector segments joining first and second ring structures of said plurality of ring structures, each o said plurality of connector segments having an undulating portion axially displaced along the longitudinal axis from said undulating portion of a circumferentially adjacent one of said plurality of connector segments. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
wherein said peak of each of said unit structures has first and second sides; and
wherein each of said first ends is connected to a first side of a first peak and each of said second ends is connected to second side of a second peak.
-
-
7. The expandable stent of claim 3, wherein said central region of at least one of said unit structures includes at least one additional peak and at least one additional valley.
-
8. The expandable stent of claim 1, wherein adjacent ring structures are aligned in phase.
-
9. The expandable stent of claim 1, wherein said undulating portion comprises a first u-shaped bend disposed between second and third u-shaped bends.
-
10. The expandable stent of claim 9, wherein said first u-shaped bend extends in a first direction, and wherein said second and third u-shaped bends extend in a second direction.
-
11. The expandable stent of claim 10, wherein said second direction is substantially opposite said first direction.
-
12. The expandable stent of claim 9, wherein said first u-shaped bend has a height, said second u-shaped bend has a first depth, and said third u-shaped bend has a second depth;
- and
wherein said first depth is substantially the same as said second depth.
- and
-
13. The expandable stent of claim 12, wherein said height is greater than said first depth.
-
14. The expandable stent of claim 1, wherein a first series of said plurality of connector segments joins first and second ring structures;
- and
wherein said undulating portions of said first series of said plurality of connector segments extend circumferentially a zig-zag pattern.
- and
-
15. The expandable stent of claim 14, wherein said undulating portion comprises a fist u-shaped bend disposed between second and third u-shaped bends.
-
16. The expandable stent of claim 15, wherein each unit structure comprises first and second lateral and a central region disposed between said first and second lateral arms, said central region having a peak disposed between first and second valleys, each said unit structure being inverted with respect to adjacent unit structures of the same ring structure.
-
17. The expandable stent of claim 16, wherein each of said plurality of connector segments is disposed between a first peak of a first unit structure of said first ring structure and a second peak of a second unit structure of said second ring structure.
-
18. The expandable stent of claim 17, wherein said first lateral arm has first and second ends;
- and
wherein said second and third u-shaped bends are axially positioned between said first and second ends of said first lateral arm of an adjacent unit structure.
- and
-
19. The expandable stent of claim 1, further comprising one or more pads extending outward from said plurality of ring structures.
-
20. The expandable stent of claim 19, wherein each of said one or more pads comprises an enlarged region spaced from one of said plurality of ring structures by a narrow throat region.
-
21. The expandable stent of claim 19, further comprising a pharmaceutical composition disposed on said one or more pads.
-
22. The expandable stent of claim 21, wherein said pharmaceutical composition comprises one or more of heparin, covalent heparin or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof;
- urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof;
a fibrinolytic agent;
a vasospasm inhibitor;
a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator;
an antimicrobial agent or antibiotic;
aspirin, ticlopidine, a glycoprotein llb/llla inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent;
colchicine or another antimitotic, or another microtubule inhibitor, dimethylsulfoxide (DMSO), a retinoid or another antisecretory agent;
cytochalasin or another actin inhibitor;
or a remodeling inhibitor;
deoxyribonucleic acid, antisense nucleotide or another agent for molecular genetic intervention;
methotrexate or another antimetabolite or antiproliferative agent;
paclitaxel;
tamoxifen citrate, Taxol®
or derivatives thereof, or other anti-cancer chemotherapeutic agents;
dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal anti-inflammatory agent;
cyclosporin or another immunosuppressive agent;
tripodal (aPDGF antagonist), angiopeptin (growth hormone antagonis), angiogenin or other growth factors, or an anti-growth factor antibody, or another growth factor antagonist;
dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist;
60Co, 192Ir, 32P, 111In, 90Y, 99mTc or another radiotherapeutic agent;
iodine-containing compounds, barium-containing compounds, gold, tantalum, platinum, tungsten another heavy metal functioning as a radiopague agent;
a peptide, a protein, an enzyme, an extracellular matrix component, a cellular component or another biologic agent;
captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor;
ascorbic acid, alpha tocopherol, superoxide dismutase, deferoxamine, a 21-amino steroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant;
a 14C—
, 3H—
, 131I, 32P- or 36S-radiolabelled form or other radiolabelled form of any of the foregoing;
estrogen or another sex hormone;
AZT or other antipolymerases;
acyclovir, famciclovir, rimantadine hydrochloride, ganciclovir sodium or other antiviral agents;
5-aminolevulinic acid, meta-tetrahydroxyphenylchlorin, hexadecaflouoro zinc phthalocyanine, tetraethyl hematoporphyrin, rhodamine 123 or other photodynamic therapy agents;
an IgG2 Kappa antibody against Pseudomonas aeruginosa exotoxin A and reactive with A431 epodermoid carcinoma cells, monoclonal antibody against the noradrenergic enzyme dopamine betahydroxylase conjugated to saporin or other antibody target therapy agents;
enalapirl or other prodrugs; and
gene therapy agents.
- urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof;
-
23. An expandable stent, comprising:
-
a main body having a list end, a second end, and a longitudinal axis extending from the first end to the second end, the main body comprising a plurality of ring structures, each of said plurality of ring structures comprising an endless pattern of unit structures, each said unit structure comprising first and second lateral arms and a central region disposed between said first and second lateral arms, said central region having a peak disposed between first and second valleys, each said it structure being inverted with respect to circumferentially adjacent unit structures; and
a plurality of connector segments joining first and second central regions of unit structures of adjacent ring structures, each of said plurality of connector segments having an undulating portion and being axially displaced along the longitudinal axis from circumferentially adjacent connector segments. - View Dependent Claims (24, 25, 26, 27)
wherein said peak of each of said unit structures has first and second sides; and
wherein each of said first ends is connected to a first side of a first peak and each of said second ends is connected to second side of a second peak.
-
-
25. The expandable stent of claim 23, wherein said undulating portion comprises a first u-shaped bend disposed between second and third u-shaped bends.
-
26. The expandable stent of claim 25, wherein said first u-shaped bend has a height, said second u-shaped end has a first depth, and said third u-shaped bend has a second depth;
- and
wherein said first depth is substantially the same as said second depth.
- and
-
27. The expandable stent of claim 26, wherein said height is greater than said first depth.
-
28. A stent having radially unexpanded and expanded configurations, the stent comprising:
-
a plurality of ring structures, each of said plurality of ring structures comprising an endless pattern of unit structures, each unit structure comprising first and second lateral arms and a central region disposed between said first and second lateral arms, said central region having a peak disposed between first and second valleys, each unit structure being inverted with respect to circumferentially adjacent unit structures; and
a plurality of connector segments joining adjacent ring structures, each of said plurality of connector segments having an undulating portion disposed between first and second ends, said undulating portion comprising a first u-shaped bend disposed between second and third u-shaped bends;
wherein each of said plurality of connector segments is axially displaced along the longitudinal axis from circumferentially adjacent connector segments when the stent is in the radially unexpanded configuration; and
wherein each of said plurality of connector segments is substantially axially aligned along the longitudinal axis with circumferentially adjacent connector segments when the stent is in the radially expanded configuration. - View Dependent Claims (29, 30)
wherein said undulating portion of each of said plurality of connector segments is substantially axially aligned with aid undulating portions of circumferentially adjacent connector segments when the stent is in the radially expanded configuration.
-
-
30. The expandable stent of claim 28, wherein said first u-shaped bend of each of said plurality of connect segments is axially displaced from said first u-shaped bends of circumferentially adjacent connector segments when the stent is in the radially unexpanded configuration;
- and
wherein said first u-shaped bend of each of said plurality of connector segments is substantially axially aligned with said first u-shaped bends of circumferentially adjacent connector segments when the stent is in the radially expanded configuration.
- and
Specification